Consecutive Aromatic Residues Are Required for Improved Efficacy of β-Sheet Breakers

Alzheimer’s disease is a fatal neurodegenerative malady which up to very recently did not have approved therapy modifying its course. After controversial approval of aducanumab (monoclonal antibody clearing β-amyloid plaques) by FDA for use in very early stages of disease, possibly new avenue opened...

Descripción completa

Detalles Bibliográficos
Autores principales: Jarmuła, Adam, Zubalska, Monika, Stępkowski, Dariusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102079/
https://www.ncbi.nlm.nih.gov/pubmed/35563639
http://dx.doi.org/10.3390/ijms23095247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102079/
https://www.ncbi.nlm.nih.gov/pubmed/35563639
http://dx.doi.org/10.3390/ijms23095247

Ejemplares similares